| Literature DB >> 31533845 |
Andrea M Rehman1, Catherine Maiteki-Sebuguzi2, Samuel Gonahasa2, Jaffer Okiring2, Simon P Kigozi2, Clare I R Chandler3, Chris Drakeley4, Grant Dorsey5, Moses R Kamya6, Sarah G Staedke7,8.
Abstract
<span class="abstract_title">BACKGROUND:n> Intermittent preventive treatment (<span class="Chemical">IPT) of <span class="Disease">malaria is recommended as policy for certain high-risk populations, but not currently for schoolchildren. A cluster-randomized trial was conducted to evaluate the effect of IPT with dihydroartemisinin-piperaquine (DP) on primary schoolchildren in Jinja, Uganda. Results of the impact of IPT of schoolchildren on community-level transmission have been reported previously. Here, secondary outcomes from a school-based survey are presented.Entities:
Keywords: Cluster-randomised trial; Dihydroartemisinin–piperaquine; Intermittent preventive treatment; Malaria; Schoolchildren
Mesh:
Substances:
Year: 2019 PMID: 31533845 PMCID: PMC6751800 DOI: 10.1186/s12936-019-2954-0
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Fig. 1Map of the study area
Fig. 2Trial profile
Characteristics of participants surveyed in the final school survey
| Characteristic | Control (n = 546) | Intervention (n = 546) |
|---|---|---|
| Age, years (mean, SE) | 10.5 (0.08) | 10.4 (0.08) |
| 5–10 years | 276 (50.5%) | 290 (53.1%) |
| 11–18 years | 270 (49.5%) | 256 (46.9%) |
| Female | 285 (52.2%) | 260 (47.6%) |
| Regiona | ||
| Urban area | ||
| Jinja town | 91 (16.7%) | 143 (26.2%) |
| Rural areas | ||
| Buwenge | 169 (31.0%) | 130 (23.8%) |
| Kakira/Busedde | 117 (21.4%) | 130 (23.8%) |
| Nile River | 169 (31.0%) | 143 (26.2%) |
| Enrolled in the interventionb | 0 (0%) | 437 (80.0%) |
| Slept under a bednet the previous nightb | 194 (35.5%) | 225 (41.2%) |
| Temperature (°C), mean (SE) | 37.1 (0.04) | 37.1 (0.04) |
aComparing urban vs rural areas, adjusting for clustering, p value = 0.29
bMissing for one child in the intervention arm
Effect of the IPT intervention on parasite prevalence in the final school survey
| n+/N | Prevalence (%) | Unadjusted risk ratio (95% CI) | p | Adjusted risk ratio (95% CI)a | p | |
|---|---|---|---|---|---|---|
| Intention to treat analysis | ||||||
| All ages | ||||||
| Control | 241/546 | 44.1 | 1 | 1 | ||
| Intervention | 50/546 | 9.2 | 0.21 (0.14–0.30) | < 0.001 | 0.22 (0.16–0.30) | < 0.001 |
| 5–10 yearsb | ||||||
| Control | 122/276 | 44.2 | 1 | 1 | ||
| Intervention | 23/290 | 7.9 | 0.18 (0.12–0.28) | < 0.001 | 0.19 (0.13–0.29) | < 0.001 |
| 11–18 yearsb | ||||||
| Control | 119/270 | 44.1 | 1 | 1 | ||
| Intervention | 27/256 | 10.6 | 0.24 (0.16–0.36) | < 0.001 | 0.25 (0.17–0.37) | < 0.001 |
| Urban areac | ||||||
| Control | 8/91 | 8.8 | 1 | 1 | ||
| Intervention | 8/143 | 5.6 | 0.64 (0.26–1.58) | 0.33 | 0.65 (0.28–1.54) | 0.33 |
| Rural areasc | ||||||
| Control | 233/455 | 51.2 | 1 | 1 | ||
| Intervention | 42/403 | 10.4 | 0.20 (0.14–0.30) | < 0.001 | 0.20 (0.14–0.29) | < 0.001 |
| Per protocol analysis | ||||||
| All ages | ||||||
| Control | 241/546 | 44.1 | 1 | 1 | ||
| Intervention | 20/438 | 4.6 | 0.10 (0.06–0.17) | < 0.001 | 0.11 (0.07–0.17) | < 0.001 |
| 5–10 yearsb | ||||||
| Control | 122/276 | 44.2 | 1 | 1 | ||
| Intervention | 9/237 | 3.8 | 0.09 (0.04–0.17) | < 0.001 | 0.09 (0.05–0.19) | < 0.001 |
| 11–18 yearsb | ||||||
| Control | 119/270 | 44.1 | 1 | 1 | ||
| Intervention | 11/201 | 5.5 | 0.12 (0.07–0.24) | < 0.001 | 0.12 (0.06–0.23) | < 0.001 |
| Urban areac | ||||||
| Control | 8/91 | 8.8 | 1 | 1 | ||
| Intervention | 5/106 | 4.7 | 0.54 (0.19–1.53) | 0.24 | 0.49 (0.18–1.38) | 0.18 |
| Rural areasc | ||||||
| Control | 233/455 | 51.2 | 1 | 1 | ||
| Intervention | 15/332 | 4.5 | 0.09 (0.05–0.16) | < 0.001 | 0.09 (0.05–0.15) | < 0.001 |
an = 1091, excluded one child with missing bednet information. Adjusted for age group (5–10, 11–18 years); baseline community parasite prevalence (quartiles: 0–13%, 13.01–25%, 25.01–33%, > 33%); sex; bednet use (slept under a bednet the previous night); and region (urban area vs rural areas)
bp-value for interaction between trial arm and age group: Intention-to-treat analysis p = 0.18 for the unadjusted model and p = 0.36 for the adjusted model; per-protocol analysis p = 0.41 for the unadjusted model and p = 0.53 for the adjusted model
cp-value for interaction between trial arm and region: Intention-to-treat analysis p = 0.02 for unadjusted model and p = 0.09 for adjusted model; per-protocol analysis p = 0.003 for the unadjusted model and p = 0.016 for the adjusted model
Fig. 3Parasite prevalence by region. For each region, the shaded bars represent the control arm and the open bars represent the intervention arm, both with 95% confidence intervals
Association between time since last dose of DP and parasite prevalence
| Treatment arm | Days since last dose of DP | Parasite prevalence | PR (95% CI)a | p-value |
|---|---|---|---|---|
| Control | No prior DP | 241/546 (44.1%) | Reference group | |
| Intervention | No prior DP | 44/168 (26.2%) | 0.57 (0.40–0.81) | 0.001 |
| 29–113 days | 3/33 (9.1%) | 0.20 (0.06–0.64) | 0.006 | |
| 1–28 days | 3/345 (0.9%) | 0.02 (0.01–0.10) | < 0.001 | |
aPrevalence ratio adjusted for repeated measures within the same cluster
Effect of the IPT intervention on secondary outcomes in the final school survey
| n/N | Prevalence (%) | Crude risk ratio (95% CI) | p | Adjusted risk ratio (95% CI) | p | |
|---|---|---|---|---|---|---|
| Prevalence of gametocytaemia | ||||||
| Control | 52/546 | 9.5 | 1 | 1 | ||
| Intervention | 17/546 | 3.1 | 0.33 (0.19–0.56) | < 0.001 | 0.34 (0.20–0.56) | < 0.001 |
| Prevalence of fever | ||||||
| Control | 307/546 | 56.2 | 1 | 1 | ||
| Intervention | 110/546 | 20.2 | 0.36 (0.25–0.51) | < 0.001 | 0.35 (0.25–0.50) | < 0.001 |
| Symptomatic malaria | ||||||
| Control | 195/546 | 35.7 | 1 | 1 | ||
| Intervention | 28/546 | 5.1 | 0.14 (0.08–0.26) | < 0.001 | 0.14 (0.08–0.26) | < 0.001 |
| Prevalence of anaemia | ||||||
| Control | 26/126 | 20.1 | 1 | 1 | ||
| Intervention | 24/129 | 18.6 | 0.90 (0.54–1.51) | 0.69 | 0.82 (0.49–1.38) | 0.46 |
| Mean haemoglobina | ||||||
| Control | 126 | 12.7 (SE 0.14) | 0 | 0 | ||
| Intervention | 129 | 12.9 (SE 0.13) | 0.15 (− 0.22, 0.52) | 0.42 | 0.19 (− 0.16, 0.54) | 0.29 |
aMeasured in every 5th participant, results presented as the relative difference in mean values